Prostate cancer

Plenary Session 2

  • Location:
    eURO Auditorium (Hall C1, Level 0)
  • Chairs:
     D. Jacqmin, Strasbourg (FR)
     M. Wirth, Dresden (DE)
  • Aims and objectives of this session

    The session deals with diagnosis and classification of patients with prostate cancer. One topic is whether genomics help us define patients with high risk disease with higher certainty and thus improve active surveillance. The other lectures deal with early diagnosis of prostate cancer, the role of multiparametric MRI and when a biopsy is indicated. Adjuvant radiotherapy is another hot topic of this session. We will learn when it should be applied.

Highlight session Highlight session 1
Lower urinary tract dysfunction
 N. Thiruchelvam, Cambridge (GB)
 A. Papatsoris, Marousi - Athens (GR)
Aims and objectives of this presentation

We present the highlights of the topic "Stones" after reviewing the relevant accepted abstracts of the Congress.

 C.F.S.J. Jensen, Herlev (DK)
Aims and objectives of this presentation

The aim of the presentation is to provide an overview of the newest discoveries and best research presented within the field of Andrology at EAU 2016.

Late breaking news
TOOKAD SolubleTM versus active surveillance in men with low risk prostate cancer – a randomized phase 3 clinical trial

By: Alcaraz A.12, Azzouzi A.R.2, Barret E.4, Benzaghou F.16, Cicco A.5, Debruyne F.M.J.15, Emberton M.1, Gaillac B. 16, Gratzke C.8, Kleinclauss F.6, Rassweiler J.9, Ahlgren G.M.14, Salomon G. 10, Solsona E. 11, Stief C.8, Tammela T.13, Van Der Poel H.7, Vincendeau S.3

Institutes: 1University College London, Dept. of Surgery and Interventional Science, London, United Kingdom, 2Angers University Hospital, Dept. of Urology, Angers, France, 3Rennes University Hospital , Dept. of Urology, Rennes, France, 4Université Paris-Descartes, Dept. of Urology, Paris, France, 5Centre Catalan Urologie Andrologie, Dept. of Urology, Cabestany, France, 6Besançon University Hospital, Saint Jacques Hospital , Dept. of Urology and Renal Transplantation, Besançon, France, 7Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, 8LMU-Klinikum der Universität München, Dept. of Urology, Munich, Germany, 9SLK Kliniken, Dept. of Urology, Heilbronn, Germany, 10Martini-Clinic Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 11Instituto Valenciano de Oncología, Dept. of Urology, Valencia, Spain, 12Hospital Clínic de Barcelona, Dept. of Urology, Barcelona, Spain, 13Tampere University Hospital, Dept. of Urology, Tampere, Finland, 14Skåne University Hospital, Dept. of Urology, Malmö, Sweden, 15Andros Clinic, Dept. of Urology, Arnhem, The Netherlands, 16Stebabiotech, Medical department , Paris, France

 D. Murphy, Melbourne (AU)
State-of-the-art lecture Is genomics going to help us find high risk disease?
 T. Schlomm, Hamburg (DE)
Debate Is there a role for pre-biopsy MRI?
 J. Walz, Marseille (FR)
 E. Baco, Oslo (NO)
Discussant European Society of Urogenital Radiology (ESUR)
 H. Thoeny, Berne (CH)
State-of-the-art lecture Prevention and management of biopsy complications
 T. Cai, Trento (IT)
Aims and objectives of this presentation

Even if prostate biopsy is generally considered a safe procedure, it may be accompanied by several clinical complications, like bleeding or, more frequently, infective complications ranging from asymptomatic bacteriuria to symptomatic UTI and sepsis. Today, the infective complications after prostate biopsy represent an important challenge for the urologist and a life-threatening risk for the patient, in particular due to the increased rate of antibiotic resistant bacteria. We need to find novel approaches and strategies for the prevention of infective complications.

Debate Timing of radiotherapy after radical prostatectomy
 J. Irani, Le Kremlin-Bicetre (FR)
 T. Wiegel, Ulm (DE)
 R.J. Karnes, Rochester (US)
State-of-the-art lecture Long term quality of life in survivors
 E.M. Johansson, Uppsala (SE)
Aims and objectives of this presentation

Due to early detection the life expectency for men with localized prostate cancer can be two decades or more, emphasizing the importance of long-term quality of life data. I will present long-term data focusing on the SPCG-4 study.

Debate When is chemotherapy indicated in hormone-naïve prostate cancer in 2016?
 K. Miller, Berlin (DE)
 K. Miller, Berlin (DE)
Results of the STAMPEDE trial: Game, set and match
 N.W. Clarke, Manchester (GB)
Will hormone therapy be lost for urologists in these cases?
 N. Mottet, Saint-Étienne (FR)
Case discussion Rising PSA after curative therapy: What to do?
 K. Touijer, New York (US)
Pro surgery
 S. Joniau, Leuven (BE)
Pro radiotherapy
 P. Ost, Ghent (BE)